Clinical Trials Browser

Interventional × Refractory Solid Tumors × Clear all

NCT06006273 2026-05-20

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Refractory Solid Tumors

NCT06150365 2025-03-26

Personalized KSX01-TCRT in Patients With Advanced Solid Tumors

Phase EARLY_PHASE1 Recruiting

Other solid neoplasm

Refractory Solid Tumors

NCT03810742 2023-11-18

Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors

Phase 1 Completed

Other solid neoplasm

Refractory Solid Tumors

NCT02450123 2022-06-15

Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors

Phase NA Completed

Other solid neoplasm

Refractory Solid Tumors

NCT02450136 2022-06-15

Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors

Phase NA Completed

Other solid neoplasm

Refractory Solid Tumors

NCT02688881 2022-06-15

Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors

Phase 4 Completed

Other solid neoplasm

Refractory Solid Tumors

NCT02691767 2022-06-15

Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors

Phase NA Completed

Other solid neoplasm

Refractory Solid Tumors

NCT02691793 2022-06-15

Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors

Phase 4 Completed

Other solid neoplasm

Refractory Solid Tumors

NCT04869475 2021-05-13

Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation

Phase 2 Unknown

Other solid neoplasm

Refractory Solid Tumors

NCT02691780 2019-12-30

Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors

Phase NA Withdrawn

Other solid neoplasm

Refractory Solid Tumors

NCT02450149 2017-03-13

Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors

Phase NA Completed

Other solid neoplasm

Refractory Solid Tumors

NCT00914914 2014-10-28

Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods of Treatment

Phase 1 Completed

Other solid neoplasm

Refractory Solid Tumors

NCT00759928 2014-07-02

PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors

Phase 1 Completed

Other solid neoplasm

Refractory Solid Tumors

NCT00394446 2008-02-13

Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors

Phase 1 Completed

Other solid neoplasm

Refractory Solid Tumors

NCT00404508 2006-11-28

A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors

Phase 2 Completed

Other solid neoplasm

Refractory Solid Tumors